Ian Stuart Fentiman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ian Stuart Fentiman has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
J. Louise Jones
16 shared publications- Jack Cuzick
John Snow Emeritus Professor of Epidemiology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK
16 shared publications - Mangesh A. Thorat
Centre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health Queen Mary University of London UK
16 shared publications - Nigel Bundred
Manchester University NHS Foundation Trust, Wythenshawe, Manchester, UK
16 shared publications Pauline M. Levey
16 shared publicationsSarah E. Pinder
16 shared publications
Latest Publications
- Open Access
- 29 October 2024
- Published by American Association for Cancer Research (AACR)
Data from Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial
Purpose:HER2 is overexpressed more frequently in ductal carcinoma in situ (DCIS) than in invasive breast cancer but its prognostic significance and predictive role for radiotherapy has not been clearly established. We investigated the prognostic and predictive value of HER2 overexpression in DCIS.Experimental Design:HER2 expression was evaluated by IHC using the HercepTest™ in samples from UK/ANZ DCIS trial participants (n = 755) with IHC 3+ expression categorized as HER2 positive for primary analyses. Sensitivity analyses included HER2 categorization as negative (IHC 0,1+), equivocal (IHC 2+), and positive (IHC 3+) and analyses restricted to a nested case–control component where 181 cases (with recurrence) were matched to 362 controls by treatment arm and age.Results:Two-hundred and forty-five (34.4%) of evaluable 713 samples [181 ipsilateral breast events (IBE)] were HER2 positive. HER2 overexpression was associated with significantly increased risk of IBE [HR = 2.29; 95% confidence interval (95% CI), 1.64–3.14; P < 0.0001] and in situ IBE (DCIS-IBE; HR = 2.90; 95% CI, 1.91–4.40; P < 0.0001), but not of invasive IBE (I-IBE; HR = 1.40; 95% CI, 0.81–2.42; P = 0.23; Pheterogeneity = 0.04). Inclusion of HER2 significantly improved [Δχ2 (1d.f.) 12.25; P = 0.0005] a prognostic model of clinicopathological and treatment variables, HER2 being an independent predictor of IBE (multivariate HR = 1.91; 95% CI, 1.33–2.76; P = 0.0004). Radiotherapy benefit in preventing DCIS-IBE was significantly greater (Pheterogeneity = 0.04) in HER2-positive DCIS (HR = 0.16; 95% CI, 0.07–0.41) compared with HER2-negative DCIS (HR = 0.58; 95% CI, 0.28–1.19).Conclusions:HER2 overexpression is associated with significantly increased risk of in situ recurrence and is also predictive of radiotherapy benefit, with greater reductions in in situ but not invasive recurrences in HER2-positive DCIS.
- 29 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial
Purpose:HER2 is overexpressed more frequently in ductal carcinoma in situ (DCIS) than in invasive breast cancer but its prognostic significance and predictive role for radiotherapy has not been clearly established. We investigated the prognostic and predictive value of HER2 overexpression in DCIS.Experimental Design:HER2 expression was evaluated by IHC using the HercepTest™ in samples from UK/ANZ DCIS trial participants (n = 755) with IHC 3+ expression categorized as HER2 positive for primary analyses. Sensitivity analyses included HER2 categorization as negative (IHC 0,1+), equivocal (IHC 2+), and positive (IHC 3+) and analyses restricted to a nested case–control component where 181 cases (with recurrence) were matched to 362 controls by treatment arm and age.Results:Two-hundred and forty-five (34.4%) of evaluable 713 samples [181 ipsilateral breast events (IBE)] were HER2 positive. HER2 overexpression was associated with significantly increased risk of IBE [HR = 2.29; 95% confidence interval (95% CI), 1.64–3.14; P < 0.0001] and in situ IBE (DCIS-IBE; HR = 2.90; 95% CI, 1.91–4.40; P < 0.0001), but not of invasive IBE (I-IBE; HR = 1.40; 95% CI, 0.81–2.42; P = 0.23; Pheterogeneity = 0.04). Inclusion of HER2 significantly improved [Δχ2 (1d.f.) 12.25; P = 0.0005] a prognostic model of clinicopathological and treatment variables, HER2 being an independent predictor of IBE (multivariate HR = 1.91; 95% CI, 1.33–2.76; P = 0.0004). Radiotherapy benefit in preventing DCIS-IBE was significantly greater (Pheterogeneity = 0.04) in HER2-positive DCIS (HR = 0.16; 95% CI, 0.07–0.41) compared with HER2-negative DCIS (HR = 0.58; 95% CI, 0.28–1.19).Conclusions:HER2 overexpression is associated with significantly increased risk of in situ recurrence and is also predictive of radiotherapy benefit, with greater reductions in in situ but not invasive recurrences in HER2-positive DCIS.
- Open Access
- 29 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial
Supplementary material including study design, cohort representativeness, senstivity analyses and supplementary references
- 29 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial
Supplementary material including study design, cohort representativeness, senstivity analyses and supplementary references
- Open Access
- 1 July 2023
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 12 (7) , 1669-1671
Neoadjuvant treatment for male breast cancer
Neoadjuvant treatment for male breast cancer
- 1 July 2023
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 12 (7) , 1669-1671
Open AccessNeoadjuvant treatment for male breast cancer
Neoadjuvant treatment for male breast cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial
Supplementary Figure 2 - Multi-clonality in ER expression in DCIS.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial
Supplementary Figure 2 - Multi-clonality in ER expression in DCIS.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
REMARK checklist from Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial
REMARK checklist referring to current accepted word version of the manuscript.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessREMARK checklist from Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial
REMARK checklist referring to current accepted word version of the manuscript.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Material from Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial
Additional study design information, figures and tables, and supplementary references
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Material from Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial
Additional study design information, figures and tables, and supplementary references
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial
Supplementary Figure 1 summarizes the treatment allocation in the UK/ANZ DCIS trial, and distribution of patients in the biomarker study subset (BSS1).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial
Supplementary Figure 1 summarizes the treatment allocation in the UK/ANZ DCIS trial, and distribution of patients in the biomarker study subset (BSS1).
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial
Supplementary Figure 1 summarizes the treatment allocation in the UK/ANZ DCIS trial, and distribution of patients in the biomarker study subset (BSS1).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial
Supplementary Figure 1 summarizes the treatment allocation in the UK/ANZ DCIS trial, and distribution of patients in the biomarker study subset (BSS1).